Gilead's China Remdesivir Patents Confirmed, Generics Firms Cautioned
US Firm Gains Upper Hand Amid Patent Dispute
Executive Summary
As the front-runner antiviral in the fight against the coronavirus gets increasingly positive attention in China, officials take action to keep the originator front and center and domestic copycats at bay.
You may also be interested in...
Hetero Head On Remdesivir Partnering, Royalty Model
Hetero is one of the new licensees for Gilead’s remdesivir, the investigational antiviral in the spotlight as a potential treatment for COVID-19, and the Indian group’s managing director shares insights on its supply chain readiness and the royalty model of the deal.
Biogen Still Not Disclosing Which Exec Has Coronavirus Infection
Public health officials in Massachusetts say Biogen company meeting is source of 70 cases in the state.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.